MA32891B1 - Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10 - Google Patents

Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10

Info

Publication number
MA32891B1
MA32891B1 MA33931A MA33931A MA32891B1 MA 32891 B1 MA32891 B1 MA 32891B1 MA 33931 A MA33931 A MA 33931A MA 33931 A MA33931 A MA 33931A MA 32891 B1 MA32891 B1 MA 32891B1
Authority
MA
Morocco
Prior art keywords
pyridine
pyrimidine derivatives
phosphodiesterase inhibitors
compulsive
compounds
Prior art date
Application number
MA33931A
Other languages
Arabic (ar)
English (en)
Inventor
Jennifer R Allen
Kaustav Biswas
Frank Chavez Jr
Ning Chen
Frenel Fils Demorin
James R Falsey
Mike Frohn
Paul Harrington
Daniel B Horne
Essa Hu
Matthew R Kaller
Roxanne Kunz
Holger Monenschein
Tom Nguyen
Alex Pickrell
Andreas Reichelt
Shannon Rumfelt
Rob Rzasa
Kelvin Sham
Guomin Yao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA32891B1 publication Critical patent/MA32891B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne des composés de pyridine et de pyrimidine, des compositions les contenant, et des processus de préparation de ces composés. L'invention concerne en outre des procédés permettant de traiter des troubles ou des maladies que l'on peut traiter par inhibition de PDE10, par exemple l'obésité, les diabètes non insulino-dépendants, la schizophrénie, le trouble bipolaire, le trouble obsessionnel compulsif, etc.
MA33931A 2008-11-14 2011-06-10 Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10 MA32891B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11459508P 2008-11-14 2008-11-14
US16621509P 2009-04-02 2009-04-02
PCT/US2009/064643 WO2010057126A1 (fr) 2008-11-14 2009-11-16 Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10

Publications (1)

Publication Number Publication Date
MA32891B1 true MA32891B1 (fr) 2011-12-01

Family

ID=41557471

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33931A MA32891B1 (fr) 2008-11-14 2011-06-10 Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10

Country Status (17)

Country Link
US (2) US8318718B2 (fr)
EP (1) EP2364306B1 (fr)
JP (1) JP2012508777A (fr)
KR (1) KR20110086603A (fr)
AR (1) AR074343A1 (fr)
AU (1) AU2009313773B2 (fr)
BR (1) BRPI0921598A2 (fr)
CA (1) CA2742833C (fr)
CR (1) CR20110279A (fr)
EA (1) EA201100749A1 (fr)
ES (1) ES2413808T3 (fr)
IL (1) IL212670A0 (fr)
MA (1) MA32891B1 (fr)
MX (1) MX2011005093A (fr)
TN (1) TN2011000220A1 (fr)
TW (1) TW201030001A (fr)
WO (1) WO2010057126A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
US8354411B2 (en) 2009-02-05 2013-01-15 Takeda Pharmaceutical Company Limited 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound
KR101875238B1 (ko) 2010-06-24 2018-07-05 다케다 야쿠힌 고교 가부시키가이샤 포스포디에스테라아제 （ｐｄｅｓ） 저해제로서의 융합 헤테로시클릭 화합물
WO2012018909A1 (fr) 2010-08-04 2012-02-09 Takeda Pharmaceutical Company Limited Composés hétérocycliques condensés
EP2602255B1 (fr) 2010-08-04 2017-04-26 Takeda Pharmaceutical Company Limited Composé à cycle hétérocyclique fusionné
JP5800814B2 (ja) 2010-08-10 2015-10-28 武田薬品工業株式会社 複素環化合物およびその用途
EP3210984B1 (fr) 2011-01-11 2019-06-19 Sunovion Pharmaceuticals Inc. Composés hétéroaryles et procédés d'utilisation correspondants
BR112013021180A2 (pt) 2011-02-18 2019-09-24 Allergan Inc derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a)
JP5973990B2 (ja) * 2011-03-16 2016-08-23 武田薬品工業株式会社 縮合複素環化合物
EA031153B1 (ru) 2011-06-10 2018-11-30 Мерк Патент Гмбх Применение пиримидиновых соединений с btk ингибирующей активностью
TWI570122B (zh) 2011-06-22 2017-02-11 武田藥品工業股份有限公司 稠合雜環化合物之結晶
WO2012177896A1 (fr) 2011-06-24 2012-12-27 Amgen Inc. Antagonistes de trpm8 et leur utilisation dans le cadre thérapeutique
JP2014527511A (ja) 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用
TWI450895B (zh) * 2011-08-25 2014-09-01 Merck Sharp & Dohme 嘧啶ｐｄｅ１０抑制劑
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2014071044A1 (fr) 2012-11-01 2014-05-08 Allergan, Inc. Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
EP2975037A4 (fr) 2013-03-15 2016-08-10 Daiichi Sankyo Co Ltd Dérivé du benzothiophène
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
CA2925211A1 (fr) 2013-09-27 2015-04-02 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisation
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
ES2795748T3 (es) 2014-07-31 2020-11-24 Pasteur Institut Korea Derivados de 2-amino-bencimidazol como inhibidores de 5-lipoxigenasa y/o prostaglandina E sintasa para tratar enfermedades inflamatorias
EP3351533A4 (fr) 2015-09-18 2019-03-06 Kaken Pharmaceutical Co., Ltd. Dérivé biaryle et médicament le contenant
CN110563664A (zh) * 2019-07-23 2019-12-13 上海合全药物研发有限公司 外消旋体(4as,7s,7as)-叔丁基-7-羟基六氢环戊二烯[b][1,4]噁嗪-4(4ah)-甲酸基酯制法
CN117337292A (zh) * 2021-05-12 2024-01-02 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
WO2003004488A1 (fr) * 2001-07-03 2003-01-16 Chiron Corporation Composes d'indazole benzimidazole utilises comme inhibiteurs de tyrosine et de serine/threonine kinase
PL1635828T3 (pl) 2003-04-04 2008-10-31 H Lundbeck As Pochodne 4-(2-fenyloksyfenylo)-piperydyny lub 1,2,3,6-tetrahydropirydyny jako inhibitory wychwytu zwrotnego serotoniny
DE10337942A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
DE10349587A1 (de) * 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
DE102005016634A1 (de) * 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
MX2008001605A (es) 2005-08-02 2008-04-14 Irm Llc Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica.
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
WO2008057280A1 (fr) 2006-10-27 2008-05-15 Amgen Inc. Composés à cycles multiples et procédés d'utilisation
WO2009081259A1 (fr) 2007-12-21 2009-07-02 Pfizer Inc. Dérivés phénoxy-pyridylés
CA2727174A1 (fr) 2008-06-20 2010-01-21 Jiangao Song Agonistes des recepteurs gpr119 aryles et utilisations associees

Also Published As

Publication number Publication date
CA2742833A1 (fr) 2010-05-20
TW201030001A (en) 2010-08-16
BRPI0921598A2 (pt) 2016-02-10
IL212670A0 (en) 2011-07-31
EA201100749A1 (ru) 2011-10-31
CA2742833C (fr) 2013-12-31
EP2364306B1 (fr) 2013-04-24
US20130079325A1 (en) 2013-03-28
AU2009313773B2 (en) 2013-03-21
EP2364306A1 (fr) 2011-09-14
US8759532B2 (en) 2014-06-24
TN2011000220A1 (en) 2012-12-17
MX2011005093A (es) 2011-09-27
AR074343A1 (es) 2011-01-12
CR20110279A (es) 2011-09-22
WO2010057126A1 (fr) 2010-05-20
KR20110086603A (ko) 2011-07-28
US20100125062A1 (en) 2010-05-20
ES2413808T3 (es) 2013-07-17
AU2009313773A1 (en) 2010-05-20
JP2012508777A (ja) 2012-04-12
US8318718B2 (en) 2012-11-27

Similar Documents

Publication Publication Date Title
MA32891B1 (fr) Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MX2008010671A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
MX2008011258A (es) Derivados de quinazolina como inhibidores de fosfodiesterasa 10.
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
MX2008010953A (es) Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
WO2006105516A3 (fr) Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MX2009006630A (es) Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa.
MX2008011175A (es) Inhibidores de fosfodiesterasa 10.
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2008033562A3 (fr) Composés inhibiteurs de kinases
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
MX2009013676A (es) Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa.
ATE544761T1 (de) Pyrimidinderivate und zusammensetzungen als c-kit-und pdgfr-kinasehemmer
ATE553093T1 (de) Indazolderivate zur hemmung von trpv1 und verwendungen davon